Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ulixertinib is an inhibitor of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 47.00 |
Description | Ulixertinib is an inhibitor of ERK protein kinase. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Upon oral administration, BVD-523 inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. |
Synonyms | Ulixertinib HCl, BVD-523, VRT752271, BVD 523, BVD523, VRT 752271 |
Molecular Weight | 469.79 |
Formula | C21H23Cl3N4O2 |
CAS No. | 1956366-10-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ulixertinib hydrochloride 1956366-10-1 Ulixertinib HCl BVD-523 VRT752271 VRT-752271 BVD 523 Ulixertinib Hydrochloride BVD523 VRT 752271 inhibitor inhibit